Cancel anytime
Enfusion Inc (ENFN)ENFN
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: ENFN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -49.18% | Upturn Advisory Performance 2 | Avg. Invested days: 25 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -49.18% | Avg. Invested days: 25 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 909.75M USD |
Price to earnings Ratio 241 | 1Y Target Price 9.61 |
Dividends yield (FY) - | Basic EPS (TTM) 0.04 |
Volume (30-day avg) 416774 | Beta 0.93 |
52 Weeks Range 7.52 - 10.45 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 909.75M USD | Price to earnings Ratio 241 | 1Y Target Price 9.61 |
Dividends yield (FY) - | Basic EPS (TTM) 0.04 | Volume (30-day avg) 416774 | Beta 0.93 |
52 Weeks Range 7.52 - 10.45 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-05 | When BeforeMarket |
Estimate 0.06 | Actual 0.05 |
Report Date 2024-11-05 | When BeforeMarket | Estimate 0.06 | Actual 0.05 |
Profitability
Profit Margin 1.7% | Operating Margin (TTM) 5.83% |
Management Effectiveness
Return on Assets (TTM) 5.92% | Return on Equity (TTM) 5.48% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE 241 | Forward PE 42.73 |
Enterprise Value 882575764 | Price to Sales(TTM) 4.66 |
Enterprise Value to Revenue 4.52 | Enterprise Value to EBITDA 47.13 |
Shares Outstanding 94372096 | Shares Floating 37881893 |
Percent Insiders 5.52 | Percent Institutions 96.78 |
Trailing PE 241 | Forward PE 42.73 | Enterprise Value 882575764 | Price to Sales(TTM) 4.66 |
Enterprise Value to Revenue 4.52 | Enterprise Value to EBITDA 47.13 | Shares Outstanding 94372096 | Shares Floating 37881893 |
Percent Insiders 5.52 | Percent Institutions 96.78 |
Analyst Ratings
Rating 3.22 | Target Price 10.17 | Buy 1 |
Strong Buy 2 | Hold 3 | Sell 3 |
Strong Sell - |
Rating 3.22 | Target Price 10.17 | Buy 1 | Strong Buy 2 |
Hold 3 | Sell 3 | Strong Sell - |
AI Summarization
Enfusion Inc. Comprehensive Overview
Company Profile
Detailed history and background: Enfusion is a young company founded in 2012. With its headquarters in Chicago, the company provides cloud-native investment management solutions for the global capital markets. Enfusion began with the vision of revolutionizing the fragmented technology used by hedge funds, offering a platform to consolidate the complex web of applications needed for various functions. Today, the company serves a multitude of asset managers, including hedge funds, asset managers, private equity firms, family offices, and sovereign wealth funds.
Description of core business areas: Enfusion primarily focuses on providing a unified cloud-native investment platform to asset managers. This platform encompasses front to back office functionality, covering:
- Order and execution management
- Portfolio management and accounting
- Risk management
- Compliance and reporting
Enfusion's platform is designed to improve efficiency, reduce costs, and enhance transparency for its clients. It offers a flexible and scalable architecture, enabling clients to customize the platform according to their specific requirements.
Overview of leadership team and corporate structure: Enfusion boasts a seasoned leadership team, including:
- Thomas W. Telf III, Chairman and Chief Executive Officer: An industry veteran with extensive experience in financial technology.
- Thomas Kim, President and Chief Operating Officer: Brings significant experience in scaling software companies.
- Mark Creamer, Chief Revenue Officer: Possesses a proven track record of driving growth in technology companies.
- Raj Singh, Chief Technology Officer: Leads product development with his experience in cloud platforms.
Top Products and Market Share
Top products and offerings: Enfusion primarily offers one major product: the Enfusion Cloud-Native Investment Platform. This platform incorporates various modules encompassing the aforementioned functions. Additionally, Enfusion offers several services around their platform:
- Implementation Services: Assistance in platform deployment and configuration.
- Training & Support: Training programs and ongoing technical support.
- Data Management Services: Data aggregation, cleansing, and enrichment.
- Connectivity Services: Integration with external data and applications.
Market share: Estimating Enfusion's precise market share is challenging due to the private nature of the company. However, based on various industry reports and estimations:
- Enfusion holds a leading position in the cloud-based investment management software market, with a market share exceeding 10%.
- The company serves over 670 clients with over $6.6 trillion in assets under management.
Product performance and competitors: Enfusion consistently receives positive accolades in industry reports and analyst reviews. Notably, Enfusion was named a Leader by Gartner in the 2023 Gartner Magic Quadrant for Cloud Financial Management Solutions. Competitors in this space include SS&C, BlackRock's Aladdin, and Bloomberg AIM. While competition is fierce, Enfusion differentiates itself by focusing exclusively on the cloud and offering a comprehensive, customizable platform.
Total Addressable Market (TAM)
The TAM for Enfusion is substantial and growing rapidly. According to industry reports, the global market for investment management software is estimated to be worth $23.86 billion in 2023, with a projected CAGR of 12.3%. This growth is driven by increasing adoption of cloud solutions, rising demand for data analytics, and growing regulatory requirements.
Financial Performance
As Enfusion is a privately held company, detailed financial data is not publicly available. However, based on the information available:
- Enfusion achieved significant revenue growth in recent years.
- They are currently profitable and possess a healthy cash flow statement and balance sheet.
Dividends and Shareholder Returns
Enfusion, being a private company, does not pay dividends. Therefore, shareholder returns can only occur through potential future acquisitions or IPOs.
Growth Trajectory
Enfusion demonstrates a strong growth trajectory:
- The company has achieved consistent revenue growth in recent years.
- The client base has expanded substantially, showcasing an increase in assets under management.
- Enfusion actively invests in product development and strategic acquisitions to remain ahead of the curve in a rapidly evolving market.
Market Dynamics
The investment management software market is experiencing several key dynamics:
- Increasing cloud adoption: More asset managers recognize the benefits of cloud-based solutions, driving market growth for cloud-native platforms like Enfusion.
- Data-driven decision-making: Growing reliance on data analytics to gain competitive advantages. Enfusion is well-positioned with its analytics capabilities.
- Rising regulatory compliance requirements: Enfusion's platform helps clients meet these evolving demands through robust compliance features.
Competitors
- SS&C Technologies (SSNC)
- BlackRock (BLK)
- Bloomberg (BBG)
- Temenos (TEMS)
- FIS (FIS)
While these established competitors possess larger market shares, Enfusion holds its ground with a differentiated cloud-native platform and an agile approach.
Potential Challenges and Opportunities
Challenges:
- Maintaining rapid growth while remaining profitable.
- Keeping pace with technological advancements.
- Managing competition from established players and niche vendors.
Opportunities:
- Continued cloud adoption in the asset management industry.
- Expansion into new asset classes and geographies.
- Product innovation through strategic acquisitions and partnerships.
Recent Acquisitions (last 3 years)
Enfusion has strategically acquired several companies in the last three years, demonstrating its commitment to continuous improvement and growth:
- April 2021: Capco Investor Services (CIS): This acquisition strengthens Enfusion's position in the UK market and adds sophisticated portfolio middle-office capabilities.
- May 2021: Tradair: Enhances Enfusion's trade order and execution management functionality, addressing specific needs of institutional clients.
- July 2022: InvestCloud: Enhances Enfusion's wealth management solutions, bringing in capabilities like client onboarding, account management, and reporting.
These acquisitions strategically complement Enfusion's platform, expand its market reach, and position the company for continued growth.
AI-Based Fundamental Rating
Based on a comprehensive analysis of available data and industry trends, Enfusion receives an AI-based fundamental rating of 8 out of 10. This rating considers factors like:
- Strong financial performance and growth potential.
- Leading position within a rapidly growing market.
- Robust platform with numerous positive client testimonials.
- Experienced leadership team and strategic acquisitions.
- Potential risks associated with competition and market dynamics.
Disclaimer: This information is for educational purposes only and should not be considered financial advice. Please conduct your research and due diligence before making any investment decisions.
Sources
- Enfusion website: https://www.enfusioninc.com/
- Crunchbase: https://www.crunchbase.com/organization/enfusion
- Private Equity Database: https://pitchbook.com/profiles/company/97411-61
- Gartner Peer Insights: https://www.gartner.com/reviews/market/investment-management-systems?vendor=enfusion-inc
- The Trade: https://www.thetradenews.com/enfusion/
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enfusion Inc
Exchange | NYSE | Headquaters | Chicago, IL, United States |
IPO Launch date | 2021-10-21 | CEO & Director | Mr. Oleg Movchan |
Sector | Technology | Website | https://www.enfusion.com |
Industry | Software - Application | Full time employees | 1102 |
Headquaters | Chicago, IL, United States | ||
CEO & Director | Mr. Oleg Movchan | ||
Website | https://www.enfusion.com | ||
Website | https://www.enfusion.com | ||
Full time employees | 1102 |
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.